Perseus Proteomics Inc. (4882) Stock Price

Perseus Proteomics is based on protein expression and antibody development technology developed at the University of Tokyo's Institute of Advanced Science and Technology. The company aims to apply antibodies for diagnostic and drug discovery targets in medical treatment. It conducts research and development of pharmaceutical products for treating cancer and other diseases, with a particular focus on creating high-performance antibody drug candidates using antibody technology.

The company operates solely in the pharmaceutical business, but is active in three areas: drug discovery, antibody research support, and antibody and reagent sales. In drug discovery, the company acquires high-performance antibodies using hybridoma and phage display methods, and generates revenue by licensing them to pharmaceutical companies. In antibody research support, it provides contract research services such as antibody development and sequence analysis to academic institutions and pharmaceutical companies.

In antibody and reagent sales, the company sells nuclear receptor antibodies that serve as biomarkers for cancer and lifestyle-related diseases as research reagents. It also provides PTX3 ELISA kits and antibody reagents for antibody-drug conjugate (ADC) research. These products are sold to researchers worldwide and support their research and development efforts.

Perseus Proteomics leverages its proprietary antibody acquisition technology to efficiently obtain pharmaceutical antibody candidates tailored to medical needs. In particular, it uses phage display and single B cell screening methods to develop high-performance antibodies that were difficult to obtain through conventional approaches. Through this, the company aims to contribute to the treatment of cancer and intractable diseases.

Perseus Proteomics advances research and development of therapeutic antibody drugs for cancer and other diseases by leveraging its proprietary protein expression technology and phage antibody library. The company's fundamental policy is to contribute to global healthcare through these technologies.

The company prioritizes pipeline development progress, pipeline expansion, and revenue growth over numerical management metrics. This approach emphasizes pipeline development that drives future revenue and guides business operations.

As a medium to long-term management strategy, Perseus Proteomics considers the continuous creation of new antibodies a critical priority. The company strengthens its research and development capabilities and secures funding to expand its development pipeline and advance clinical development.

The company's business environment benefits from growing demand for antibody drugs as the biopharmaceutical market expands. Within this growth trajectory, the company aims to develop antibody drugs addressing high medical needs and achieve business growth.

Perseus Proteomics advances development and expansion of its existing pipeline while conducting exploratory research for next-generation candidates. Through collaborative research with academic institutions, the company collects evaluation data on new candidate targets and actively adopts new technologies.

The company also seeks to expand antibody research support services and antibody and reagent sales, targeting revenue growth through new product launches and identification of customer needs. Additionally, the company focuses on providing new services aligned with industry trends.

Research and development funding is secured through licensing agreements, partnerships, and capital market financing. This enables the company to sustain continuous research and development efforts.

Finally, to strengthen its corporate foundation, the company is committed to recruiting talented personnel and creating a workplace environment where employees can thrive. These efforts promote employee growth and strengthen the company's foundation.